Developments in oral immunization delivery viewed as potential weapon to combat global health threats such as tuberculosis, AIDS and diarrheas
Scientists at The Forsyth Institute and Tufts University have succeeded in describing and validating a unique system of oral vaccine delivery using a common bacteria found in the mouth. Findings published today by Elsevier in Microbes and Infection identify Streptococcus mitis as a successful vector for oral mucosal immunization, and further research will determine its potential clinical use in tuberculosis vaccine development.
“Although injected vaccines are traditionally viewed as effective means of immunization to protect internal organs, these vaccines rarely induce strong mucosal protection in the gastrointestinal tract, respiratory tract and genitalia. In contrast, oral vaccinations have the potential to affordably, safely and effectively protect these areas, thus assisting in the fight against global health threats including diarrheas and diseases such as tuberculosis and AIDS,” said lead research Dr. Antonio Campos-Neto, a senior member of the Department of Immunology and Infectious Diseases at The Forsyth Institute. Dr. Campos-Neto is also the director for the Center for Global Infectious Disease Research, and lecturer at the Harvard School of Dental Medicine.
According to the World Health Organization, nine million people were diagnosed with tuberculosis in 2013, the latest year in which data is available, and 1.5 million people died from the disease. It is second only to HIV/AIDS in prevalence.
The Latest on: Oral vaccine
via Google News
The Latest on: Oral vaccine
- Analysis: Omicron Is a Wake-Up Call for COVID-19 Vaccine Developerson December 8, 2021 at 10:47 am
Arrival of the highly-mutated Omicron variant is a wake-up call to develop vaccines less susceptible to the rapid changes of the coronavirus, leading virologists and immunologists told Reuters. Most ...
- Pfizer CEO says fourth Covid vaccine doses may be needed sooner than expected due to omicronon December 8, 2021 at 9:06 am
"When we see real world data will determine if the omicron is well covered by the third dose and for how long," Pfizer CEO Albert Bourla told CNBC.
- Hearing set in NYPD detective’s challenge to de Blasio’s vaccine mandateon December 8, 2021 at 6:01 am
Anthony Marciano, who’s been on the force for 10 years, claims city officials lack the “legal authority” to enact a vaccine mandate, since state lawmakers have not passed laws on it.
- Federal judge blocks vaccine requirement for federal contractors, sides with Attorney General Alan Wilsonon December 7, 2021 at 8:02 pm
Judge Stan Baker of the U.S. Court for the Southern District of Georgia sided with the South Carolina Attorney General Alan Wilson and issued an injunction against enforcing the vaccine mandate after ...
- Judge blocks vaccine requirement for federal contractorson December 7, 2021 at 2:19 pm
A federal judge has blocked the vaccine requirement for federal contractors. Judge Stan Baker in the U.S. Court for the Southern District of Georgia (Augusta) heard oral arguments Friday and issued a ...
- No, taking activated charcoal won't affect COVID-19 vaccineson December 7, 2021 at 11:42 am
Doctors say since activated charcoal is ingested orally and does not enter a person’s bloodstream, it won’t affect the COVID-19 vaccines.
- Covid vaccine efforts can't let up because of new pills from Merck and Pfizer to treat the viruson December 6, 2021 at 7:22 pm
New oral medications that fight Covid-19 are here, and they represent a major advance in the fight against the pandemic. Last week, in a controversial 13-10 vote, the Food and Drug Administration ...
- Mayo Clinic research on oral pill vaccineson December 6, 2021 at 2:58 pm
Mayo Clinic is conducting research on possible oral pills that can be taken to combat the virus. Research has been conducted using two types of pills: antiviral and monoclonal antibodies. With ...
- Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concernon December 1, 2021 at 5:03 am
Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern.
- Oravax To Develop Israeli Oral COVID-19 Vaccine in Mexicoon November 28, 2021 at 3:22 am
Oramed’s Oravax Medical and Genomma Lab Internacional in Mexico partner to develop and commercialize Oramed's oral COVID-19 vaccine .
via Bing News